Article Text

Download PDFPDF

AB0208 Hospitalization rates in patients with ra by poor prognostic factors: impact of abatacept and other disease-modifying antirheumatic therapies
  1. E Alemao,
  2. L Burns,
  3. Z Guo
  1. Bristol-Myers Squibb, Princeton, United States


Background Studies have reported that poor prognostic factors (PPF) in RA, such as high anti-citrullinated protein antibodies (ACPA), are associated with erosions, rapid radiographic progression and/or extra-articular manifestations.1,2 Evidence from clinical trials and clinical practice indicate differences in treatment effects of biologic (b)DMARDs by ACPA status and/or level.3,4 PPF also play an important role in clinical management of patients (pts) with RA, including inpatient admissions.

Objectives To compare hospitalization rates of ACPA-positive (+) with ACPA-negative (–) pts managed with abatacept (ABA), non-ABA bDMARDs or conventional (c)DMARDs.

Methods This is a retrospective cohort analysis of Clinformatics Data Mart, a database of administrative health claims including results for outpatient laboratory tests, processed by national laboratory vendors under contract with the managed care organization, for a total of ∼53 million unique lives over 13 years. This analysis was restricted to adult pts (aged ≥18 years) who had at least two ICD-9-CM diagnosis codes for RA between Jan 2007 and Dec 2014 (identification period) and 12 months (M) of membership/drug benefit. Pts with ankylosing spondylitis, Crohn's disease, lupus, psoriasis or ulcerative colitis at or before the index date were excluded. ACPA+ was based on >19 or >5 U/mL, depending on the test utlilized. Follow-up for pts initiating ABA was from first day of treatment to first hospitalization, end of enrolment or end of 12M follow-up. The primary outcome was all-cause hospitalization at 12M. Descriptive statistics such as Wilcoxon rank-sum test for continuous variables or Pearson's chi-square test for categorical variables were used. Cox proportional hazard model was used to examine all-cause hospitalization adjusted for age, sex, region and past hospitalization. Additional covariates included co-morbidities that were different between ACPA+/– pts. Similar analyses were performed for pts treated with cDMARDs and non-ABA bDMARDs.

Results A total of 496 ABA, 7438 cDMARD and 2118 non-ABA bDMARD pts were included, with an overall past hospitalization rate of 35.5, 25.4 and 23.2%, respectively. Overall, 59.5, 41.5 and 51.7% of pts were ACPA+ in the ABA, cDMARD and non-ABA bDMARD cohorts, respectively. ACPA+ pts were older and less likely to have obstructive sleep apnoea, depression and myalgia/myositis across all cohorts. Unadjusted 12M hospitalization rate in ACPA+ vs ACPA– pts was 10.8 vs 16.4%, 13.7 vs 14.3% and 8.5 vs 10.8% in the ABA, cDMARD and non-ABA bDMARD cohorts, respectively. After controlling for baseline covariates, the hazard ratio for hospitalization in the ACPA+ (vs ACPA–) group was 0.57 (95% CI: 0.34, 0.98; p=0.04), 0.95 (95% CI: 0.84, 1.08; p=0.47) and 0.88 (95% CI; 0.66, 1.17; p=0.38) in the ABA, cDMARD and non-ABA bDMARD cohorts, respectively (Figure).

Conclusions ACPA+ pts with RA treated with abatacept have a lower rate of hospitalization than ACPA– pts. This pattern was not observed with cDMARDs or non-abatacept bDMARDs. Further efforts including matching and subgroup analysis should be explored for direct comparisons between the cohorts.


  1. Visser K, et al. Ann Rheum Dis 2010;69:1333–7.

  2. Combe B, et al Ann Rheum Dis 2016; doi: 10.1136/annrheumdis-2016–210602. [Epub ahead of print].

  3. Gottenberg JE, et al. Ann Rheum Dis 2012;71:1815–9.

  4. Sokolove J, et al. Ann Rheum Dis 2016;75:709–14.


Disclosure of Interest E. Alemao Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, L. Burns Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Z. Guo Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.